GLP-1RA与SGLT2抑制剂对CKD患者肾周脂肪组织的影响
本研究纳入ADIPO-CKD前瞻性队列中80例完成基线和8个月超声随访的CKD 1–4期患者,分为未用药、SGLT2i和GLP-1RA为基础治疗三组。结果显示GLP-1RA为基础治疗和SGLT2i均与肾周脂肪厚度下降相关,且变化与体重及身体成分变化无明显相关。
要点
- GLP-1RA为基础治疗与肾周脂肪厚度显著下降相关
- SGLT2i也与肾周脂肪厚度下降相关
- 肾周脂肪变化与体重和身体成分变化无明显相关
核心结论
- 在CKD患者中,GLP-1RA为基础治疗和SGLT2i均与随访时较低的肾周脂肪厚度相关
- 肾周脂肪厚度变化不能用测量的身体成分变化解释
- 肾周脂肪可能是药物作用的脂肪库特异性靶点之一
研究设计与样本
- 前瞻性ADIPO-CKD起始队列中277例CKD 1–4期患者,80例完成基线和8个月超声配对检查
- 三组分别为未用两类药物的参考组32例、SGLT2i组24例、GLP-1RA为基础治疗组24例
- 肾周脂肪厚度取左右两侧测量均值,同时评估心外膜脂肪和身体成分
主要发现
- 参考组肾周脂肪厚度无变化,为+0.035 cm,p=0.376
- SGLT2i组肾周脂肪厚度下降−0.273 cm,−20.4%,p=0.0006
- GLP-1RA为基础治疗组下降−0.463 cm,−36.2%,p<0.0001
- 与参考组校正后差异:SGLT2i为−0.227 cm(95% CI −0.417至−0.036),GLP-1RA为基础治疗为−0.433 cm(95% CI −0.622至−0.244)
- 多重填补后差异:SGLT2i为−0.218 cm(95% CI −0.482至+0.046),GLP-1RA为基础治疗为−0.421 cm(95% CI −0.693至−0.149)
关键数值与推荐
- 肾周脂肪厚度为左右两侧测量均值
- 随访肾周脂肪厚度采用协方差分析,并校正基线值
临床怎么用
- 在CKD 1–4期患者中,GLP-1RA为基础治疗和SGLT2i均可能降低肾周脂肪厚度
- GLP-1RA为基础治疗对肾周脂肪厚度的下降幅度大于SGLT2i
- 两种药物的肾周脂肪变化与整体体重和身体成分变化无明显关联,提示脂肪库特异性效应
局限性
- 完成配对研究的患者仅80例,样本量有限
- 多重填补下SGLT2i组置信区间包含无差异,估计不够稳定
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims Perirenal adipose tissue (PRAT) surrounds the kidney and may contribute to chronic kidney disease (CKD) progression. SGLT2 inhibitors have been associated with reductions in this depot, but PRAT has not been quantified under GLP-1RA-based therapy in CKD. We assessed ultrasound-measured PRAT thickness under both treatments and whether changes tracked weight loss. Materials and Methods Adults with CKD Stages 1–4 in the prospective ADIPO-CKD inception cohort underwent ultrasound at baseline and at the 8-month visit. PRAT thickness was the mean of right and left measurements; epicardial adipose tissue and body composition were also assessed. Patients received neither drug class (reference), SGLT2i or GLP-1RA-based therapy. Follow-up PRAT was analysed by covariance analysis adjusted for baseline. Results Of 277 patients, 80 had paired studies (32 reference, 24 SGLT2i, 24 GLP-1RA-based; body weight 46–122 kg). PRAT was unchanged in the reference group (+0.035 cm, p = 0.376) and decreased with SGLT2i (−0.273 cm, −20.4%, p = 0.0006) and GLP-1RA-based therapy (−0.463 cm, −36.2%, p < 0.0001). Adjusted differences versus reference were −0.227 cm (95% CI −0.417 to −0.036) and −0.433 cm (−0.622 to −0.244); under multiple imputations, −0.218 cm (−0.482 to +0.046) and −0.421 cm (−0.693 to −0.149). GLP-1RA-based therapy reduced body weight, fat mass and visceral fat area; SGLT2i only body weight, modestly. PRAT change correlated with none. Conclusions In CKD, both drug classes were associated with lower follow-up PRAT, not explained by measured body-composition change. Under multiple imputations, both estimates were essentially unchanged, though the SGLT2i interval included no difference. PRAT may represent a candidate depot-specific target. Trial Registration ClinicalTrials.gov identifier: NCT07309094 (ADIPO-CKD)
引用
- Diabetes, Obesity and Metabolism:The Effects of GLP‐1RA‐Based and SGLT2 Inhibitor Therapy on Perirenal Adipose Tissue in CKD Patients
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。